Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 53, Issue 11, 2014, Pages 1984-1993

  Fleischmann, Roy ^a   Koenig, Andrew S ^b   Szumski, Annette ^b   Nab, Henk W ^b   Marshall, Lisa ^b   Bananis, Eustratios ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b PFIZER INC   (United States)

Author keywords

DMARDs; Etanercept; Hydroxychloroquine; Leflunomide; Methotrexate; Rheumatoid arthritis; Sulfasalazine

Indexed keywords

ETANERCEPT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GOOD CLINICAL PRACTICE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS; STEADY STATE; TREATMENT OUTCOME;

EID: 84911487889     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu235     Document Type: Article

References (19)

1. Feely MG, O'Dell JR. Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis. Curr Opin Rheumatol 2010; 22:316-20.
2. Moreland LW, O'Dell JR, Paulus HE et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheum 2012;64: 2824-35.
3. O'Dell JR, Mikuls TR, Taylor TH et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 2013;369:307-18.
4. Fleischmann R, Kavanaugh A, Smolen J. Methodological aspects and the interpretation of clinical trial data: lessons from the TEAR trial. Rheumatology 2013;52: 409-10.
5. Kim HY, Hsu PN, Barba M et al. Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial. Int J Rheum Dis 2012;15:188-96.
6. Machado D, Guzman R, Xavier R et al. Open-label observation of etanercept versus conventional diseasemodifying antirheumatic drugs in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region. J Clin Rheumatol 2014;20:25-33.
7. van Vollenhoven RF, Ernestam S, Geborek P et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009;374: 459-66.
8. van Vollenhoven RF, Geborek P, Forslind K et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 2012;379:1712-20.
9. Mok CC, van der Kleij D, Wolbink GJ. Drug levels, antidrug antibodies, and clinical efficacy of the anti-TNFalpha biologics in rheumatic diseases. Clin Rheumatol 2013;32: 1429-35.
10. Wolbink GJ, Vis M, Lems W et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:711-5.
11. O'Dell JR, Leff R, Paulsen G et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1164-70.
12. Aletaha D, Ward MM. Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials. Ann Rheum Dis 2006;65:227-33.
13. Aletaha D, Strand V, Smolen JS, Ward MM. Treatmentrelated improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. Ann Rheum Dis 2008;67:238-43.
14. Emery P, Kvien TK, Combe B et al. Combination etanercept and methotrexate provides better disease control in very early (≤4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study. Ann Rheum Dis 2012;71: 989-92.
15. Koike T, Harigai M, Inokuma S et al. Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis. Rheumatol Int 2012;32:1511-9.
16. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000; 43:22-9.
17. Combe B, Landewe R, Lukas C et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34-45.
18. Keystone E, Freundlich B, Schiff M, Li J, Hooper M. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA. J Rheumatol 2009;36: 522-31.
19. O'Dell JR, Curtis JR, Mikuls TR et al. Validation of the methotrexate-first strategy in patients with early, poorprognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. Arthritis Rheum 2013;65: 1985-94.